# ALPINE: Maintenance Letrozole/Abemaciclib

> **NCT06366347** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 32 (estimated)

## Conditions studied

- Endometrial Cancer
- Recurrent Endometrial Cancer
- TP53

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Letrozole
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06366347
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2027-09-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06366347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06366347, "ALPINE: Maintenance Letrozole/Abemaciclib". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06366347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*